https://www.bloomberg.com/news/articles/2023-01-26/white-house-under-pressure-to-develop-a-plan-b-on-student-debt#xj4y7vzkg
Piper Sandler Initiates Coverage On Verona Pharma with Overweight Rating, Announces Price Target of $31
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Verona Pharma (NASDAQ:VRNA) with a Overweight rating and announces Price Target of $31.